Listado actualizado de los 287 desarrollos con relación a la vacuna contra el covid-19 en todo el mundo.
Tipo de Vacuna Candidata | Plataforma | Desarrollador | Estado de la evaluación clínica |
---|---|---|---|
3 nanopartículas lipídicas de ARNm | ARN | BioNTech/Fosun Pharma/Pfizer socio CAEME | Aprobada |
Inactivada | Inactivada | Wuhan Institute of Biological Products/Sinopharm | Aprobada |
ChAdOx1-S | Vector viral no replicante | University of Oxford/AstraZeneca socio CAEME | Aprobada |
Gam-COVID-Vac Adeno-based | Vector viral no replicante | Gamaleya Research Institute | Aprobada |
Ad26 – Adenovirus recombinante serotipo 26 | Vector viral no replicante | Janssen Pharmaceutical Companies socio CAEME | Aprobada |
ARNm encapsulado en nanopartículas lipídicas (LNP) | ARN | Moderna/NIAID | Aprobada |
Inactivada + alumbre | Inactivada | Sinovac | Aprobada |
Inactivada | Inactivada | Beijing Institute of Biological Products/Sinopharm | Aprobada |
Vector de adenovirus tipo 5 | Vector viral no replicante | CanSino Biological Inc./Beijing Institute of Biotechnology | Aprobada |
Whole-Virion Inactivated | Inactivada | Bharat Biotech | Fase 3 |
Vacuna de nanopartículas de glucoproteína del CoV-2 SARS, recombinante, de longitud completa, adyuvada con Matrix M | Subunidad Proteica | Novavax | Fase 3 |
SARS-CoV-2 mRNA vaccine (ARCoV) | ARN | Walvax Biotechnology and Suzhou Abogen Biosciences | Fase 3 |
Proteína recombinante, adyuvada (Dímero RBD) | Subunidad Proteica | Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology Chinese Academy of Sciences | Fase 3 |
VLA2001 | Inactivada | Valneva / National Institute for Health Research / United Kingdom | Fase 3 |
ARNm | ARN | Curevac | Fase 3 |
Inactivated SARS-CoV-2 vaccine (Vero cell) | Inactivada | Shenzhen Kangtai Biological Products Co Ltd. | Fase 3 |
EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) | Subunidad Proteica | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Fase 3 |
Inactivada | Inactivada | Chinese Academy of Medical Sciences | Fase 3 |
CIGB-66 (RBD+aluminium hydroxide) | Subunidad Proteica | Center for Genetic Engineering and Biotechnology (CIGB) | Fase 3 |
Inactivada | Inactivada | Research Institute for Biological Safety Problems/Rep of Kazakhstan | Fase 3 |
Vacuna de ADN plasmídico | ADN | Osaka University/ AnGes/ Takara Bio | Fase 3 |
Vacuna de ADN plasmídico | ADN | Zydus Cadila | Fase 3 |
Vacuna de ADN plasmídico con electroporación | ADN | Inovio Pharmaceuticals | Fase 2/2 |
UB-612 (Multitope peptide based S1-RBD-protein based vaccine) | Subunidad Proteica | Vaxxinity | Fase 2/2 |
COVAX-19® Recombinant spike protein + adjuvant | Subunidad Proteica | Vaxine Pty Ltd./CinnaGen Co | Fase 2 |
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) | Subunidad Proteica | Guangdong Provincial Center for Disease Control and Prevention/Gaozhou Center for Disease Control and Prevention | Fase 2 |
COVAC-1 and COVAC-2 sub-unit vaccine (spike protein) + SWE adjuvant | Subunidad Proteica | University of Saskatchewan | Fase 2 |
Razi Cov Pars, recombinant spike protein | Subunidad Proteica | Razi Vaccine and Serum Research Institute | Fase 2 |
Inactivada | Inactivada | Beijing Minhai Biotechnology Co. Ltd. | Fase 1/2 |
Vacuna basada en ADN (GX-19) | ADN | Genexine Consortium | Fase 1/2 |
Basada en RBD | Subunidad Proteica | Kentucky Bioprocessing | Fase 1/2 |
COVID-eVax, a candidate plasmid DNA vaccine of the Spike protein | ADN | Takis + Rottapharm Biotech | Fase 1/2 |
Proteína S (producción de baculovirus) | Subunidad Proteica | Sanofi Pasteur/GSK socio CAEME | Fase 1/2 |
Inactivated (NDV-based) chimeric vaccine with or without the adjuvant CpG 1018 | Inactivada | The Government Pharmaceutical Organization (GPO) / PATH / Dynavax | Fase 1/2 |
GLS-5310 | ADN | GeneOne Life Science | Fase 1/2 |
SC-Ad6-1, Adneviral vector vaccine | Vector viral no replicante | Tetherex Pharmaceuticals Corporation | Fase 1/2 |
AdCLD-CoV19 (adenovirus vector) | Vector viral no replicante | Cellid Co / Ltd | Fase 1/2 |
Subunidad de Proteína Potenciada (RBD) | Subunidad Proteica | Biological E Ltd | Fase 1/2 |
Recombinant Sars-CoV-2 Spike protein, Aluminum adjuvanted (Nanocovax) | Subunidad Proteica | Nanogen Pharmaceutical Biotechnology | Fase 1/2 |
Recombinant SARS-CoV-2 Vaccine (CHO cell) | Subunidad Proteica | National Vaccine and Serum Institute China | Fase 1/2 |
SARS-CoV-2-RBD-Fc fusion protein | Subunidad Proteica | University Medical Center Groningen + Akston Biosciences Inc. | Fase 1/2 |
VSV-S | Vector viral replicante | Israel Institute for Biological Research/Weizmann Institute of Science | Fase 1/2 |
ARCT-021 | ARN | Arcturus/Duke-NUS | Fase 2 |
Recombinant protein vaccine S-268019 (using Baculovirus expression vector system) | Subunidad Proteica | Shionogi | Fase 1/2 |
COVIVAC. Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein +/- adjuvant CpG 1018 | Vector viral no replicante | Institute of Vaccines and Medical Biologicals / Vietnam | Fase 1/2 |
Dendritic cell vaccine AV-COVID-19. A vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF | Vector viral replicante | Aivita Biomedical Inc / National Institute of Health Research and Development / Ministry of Health Republic of Indonesia | Fase 1/2 |
CIGB-669 (RBD+AgnHB) | Subunidad Proteica | Center for Genetic Engineering and Biotechnology (CIGB) | Fase 1/2 |
LV-SMENP-DC vaccine. Dendritic cells are modified with lentivirus vectors expressing Covid-19 minigene SMENP and immune modulatory genes. CTLs are activated by LV-DC presenting Covid-19 specific antigens. | Vector viral no replicante | Shenzhen Geno-Immune Medical Institute | Fase 1/2 |
GBP510, a recombinant surface protein vaccine with adjuvant AS03 (aluminium hydroxide) | Subunidad Proteica | SK Bioscience Co Ltd and CEPI | Fase 1/2 |
EuCorVac-19; A spike protein using the recombinant protein technology and with an adjuvant. | Subunidad Proteica | POP Biotechnologies and EuBiologics Co Ltd | Fase 1/2 |
RBD-HBsAg VLPs | VLP | SpyBiotech/Serum Institute of India | Fase 1/2 |
CORVax – Spike (S) Protein Plasmid DNA Vaccine | ADN | Providence Health & Services | Fase 1 |
Chimpanzee Adenovirus serotype 68 (ChAd) and self-amplifying mRNA (SAM) vectors expressing spike alone, or spike plus additional SARS-CoV-2 T cell epitopes. | Vector viral no replicante | Gritstone Oncology | Fase 1 |
COH04S1 (MVA-SARS-2-S) – Modified vaccinia ankara (sMVA) platform + synthetic SARS-CoV-2 | Vector viral no replicante | City of Hope Medical Center + National Cancer Institute | Fase 1 |
CoV2 SAM (LNP) vaccine. A self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform + Spike antigen | ARN | GlaxoSmithKline | Fase 1 |
COVIGEN | ADN | University of Sydney / Bionet Co / Ltd Technovalia | Fase 1 |
CoV2-OGEN1, protein-based vaccine | Subunidad Proteica | VaxForm | Fase 1 |
Adjuvanted inactivated vaccine against SARS-CoV-2 | Inactivada | The Scientific and Technological Research Council of Turkey (TÜBITAK) | Fase 1 |
MV-014-212, a live attenuated vaccine that expresses the spike (S) protein of SARS-CoV-2 | Virus vivo atenuado | Meissa Vaccines / Inc. | Fase 1 |
AdimrSC-2f (recombinant RBD +/- Aluminium) | Subunidad Proteica | Adimmune Corporation | Fase 1 |
Live recombinant Newcastle Disease Virus (rNDV) vector vaccine | Inactivada | Laboratorio Avi-Mex | Fase 1 |
CoVepiT vaccine: SARS-CoV-2 multi-target peptide vaccine (targeting Spike, M, N, and several non-structural proteins) | Subunidad Proteica | OSE immunotherapeutics | Fase 1 |
ReCOV: Recombinant two-component spike and RBD protein COVID-19 vaccine (CHO cell). | Subunidad Proteica | Jiangsu Rec-Biotechnology | Fase 1 |
ChulaCov19 mRNA vaccine | ARN | Chulalongkorn University | Fase 1 |
Covid-19/aAPC vaccine. The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune modulatory genes and the viral minigenes to the artificial antigen presenting cells (aAPCs). | Vector viral replicante | Shenzhen Geno-Immune Medical Institute | Fase 1 |
SpFN (spike ferritin nanoparticle) uses spike proteins with a liposomal formulation QS21 (ALFQ) adjuvant. | Subunidad Proteica | Walter Reed Army Institute of Research (WRAIR) | Fase 1 |
MF59 adjuvanted SARS-CoV-2 Sclamp vaccine | Subunidad Proteica | The University of Queensland | Fase 1 |
Tecnología de Virus quimérico VSV apto para replicación (VSVΔG) que administra la glucoproteína de la Espiga (S) del SARS-CoV-2. | Vector viral replicante | IAVI/Merck socio CAEME | Fase 1 |
SK SARS-CoV-2 recombinant surface antigen protein subunit (NBP2001) + adjuvanted with alum. | Subunidad Proteica | SK Bioscience Co Ltd | Fase 1 |
Inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) | Inactivada | Organization of Defensive Innovation and Research | Fase 1 |
Codificación de vector adenoviral simio de replicación defectuosa (GRAd) SARS-CoV-2 S | Vector viral no replicante | ReiThera/LEUKOCARE/Univercells | Fase 1 |
Ad5-nCoV | Vector viral no replicante | Institute of Biotechnology/ Academy of Military Medical Sciences/ PLA of China | Fase 1 |
Plataforma de vacuna oral | Vector viral no replicante | Vaxart | Fase 1 |
MVA-SARS-2-S | Vector viral no replicante | Ludwig-Maximilians/ University of Munich | Fase 1 |
Vacuna de subunidad de proteína S trimérica similar a la nativa | Subunidad Proteica | Clover Biopharmaceuticals Inc/GSK/Dynavax socio CAEME | Fase 1 |
Proteína S recombinante con Advax ™ potenciador | Subunidad Proteica | Vaxine Pty Ltd/Medytox | Fase 1 |
Proteína S estabilizada por pinza molecular | Subunidad Proteica | University of Queensland/CSL/Seqirus socio CAEME | Fase 1 |
Proteína S-2P + CpG 1018 | Subunidad Proteica | Medigen Vaccine Biologics Corporation/NIAID/Dynavax | Fase 1 |
rRBD produced in CHO-cell chemically conjugate to tetanus toxoid | Subunidad Proteica | Instituto Finlay de Vacunas Cuba | Fase 1 |
RBD + Adjuvant | Subunidad Proteica | Instituto Finlay de Vacunas Cuba | Fase 1 |
ARNm | ARN | FBRI SRC VB VECTOR Rospotrebnadzor Koltsovo | Fase 1 |
RBD (baculovirus production expressed in Sf9 cells) | Subunidad Proteica | West China Hospital/ Sichuan University | Fase 1 |
SARS-CoV-2 HLA-DR peptides | Subunidad Proteica | University Hospital Tuebingen | Fase 1 |
S1-RBD-protein | Subunidad Proteica | COVAXX | Fase 1 |
bacTRL-Spike | ADN | Symvivo | Fase 1 |
V591-001 – Measles-vector based (TMV-o38) | Vector viral replicante | Institute Pasteur/Themis/Univ of Pittsburg Center for Vaccine Research/Merck socio CAEME | Fase 1 |
Intranasal flu-based-RBD | Vector viral no replicante | Beijing Wantai Biological Pharmacy/ Xiamen University | Fase 1 |
saRNA | ARN | Imperial College London | Fase 1 |
ARNm | ARN | People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech. | Fase 1 |
[E1-, E2b-, E3-] hAd5- COVID19- Spike/nucleocápside | Vector viral no replicante | ImmunityBio Inc & NantKwest Inc | Fase 1 |
VLP vegetal | VLP | Medicago Inc. | Fase 1 |
DNA, engineered vaccine inserts compatible with multiple delivery systems | ADN | DIOSynVax Ltd / University of Cambridge | Pre-clínica |
Live attenuated bacterial (Pertussis) Vector | LABV | Institut Pasteur Lille / Inserm | Pre-clínica |
The 3 regions of SARS-Cov-2 Spike-protein: NTD, RBD and HR1-HR2 inserted into the plasmid of PcDNA3.1 (+). | ADN | Center of Genomics and Bioinformatics of Academy of Science of Republic of Uzbekistan | Pre-clínica |
Live attenuated bacterial vector | LABV | ALtraBio / TheRex | Pre-clínica |
msDNA vaccine | ADN | Mediphage Bioceuticals/University of Waterloo | Pre-clínica |
DNA Immunostimulatory sequences | ADN | Inserm | Pre-clínica |
DNA plasmid vaccine encoding RBD | ADN | Vaccibody / Oslo Research Park / Norway | Pre-clínica |
Recombinant, prefusion stabilized SARS-CoV-2 Spike antigen | ARN | Medigen Vaccines Biologics Corp (MVC)/Vaxess Technologies (MIMIX) | Pre-clínica |
Protein peptides with alum | Subunidad Proteica | Hacettepe University Turkey | Pre-clínica |
Recombinant protein RBD fusion dimer adjuvanted vaccine (COVID-19 Vaccine Hipra) | Subunidad Proteica | HIPRA SCIENTIFIC SLU; LABORATORIOS HIPRA SA | Pre-clínica |
S protein integrated in HIV VLPs | VLP | IrsiCaixa AIDS Research/IRTACReSA/Barcelona Supercomputing Centre/Grifols | Pre-clínica |
Péptidos VLP / virus completo | VLP | Univ of Sao Paulo | Pre-clínica |
Desconocida | Desconocida | Tulane University | Pre-clínica |
ZIP1642 is a self-amplifying RNA vaccine encapsulated in an LNP, which encodes for multiple antigens, including the Spike (S) protein. | ARN | Ziphius Vaccines and Ghent University | Pre-clínica |
eVLP – Partícula pseudovírica envolvente | VLP | ARTES Biotechnology | Pre-clínica |
Encapsulated mRNA | ARN | CEA | Pre-clínica |
Development of recombinant protein based S1 and S2 (Spike) and nucleocapsid subunits vaccines using a plant expression vector. | Subunidad Proteica | Akdeniz University Department of Agricultural Biotechnology Antalya Turkey | Pre-clínica |
Recombinant protein subunit vaccine | Subunidad Proteica | Pharmada Pharmaceuticals/TURKEY | Pre-clínica |
Replicating VSV vector-based DC-targeting | Vector viral replicante | University of Manitoba | Pre-clínica |
Intranasal Newcastle disease virus vector (rNDV-LS1-FARVET) expressing S1 protein: rNDV-LS1-S1-F/SARS-CoV-2 | Vector viral replicante | Farmacológicos Veterinarios SAC (FARVET SAC) | Pre-clínica |
VLP | VLP | OSIVAX | Pre-clínica |
Intranasal Newcastle disease virus vector (rNDV-LS1-FARVET) expressing RBD protein: rNDV-LS1-HN-RBD/SARS-CoV-2 | Vector viral replicante | Farmacológicos Veterinarios SAC (FARVET SAC) | Pre-clínica |
Recombinant SARS CoV-2 RBD Protein, Alum adjuvanted | Subunidad Proteica | Bio Farma + Baylor College Medicine | Pre-clínica |
Lentiviral Vector | Vector viral no replicante | Theravectys – Institut Pasteur | Pre-clínica |
Recombinant Protein Vaccine | Subunidad Proteica | Ataturk University Vaccine Research Center (Erzurum) and Health Institutes of Turkey (TUSEB) | Pre-clínica |
Recombinant Spike Protein | Subunidad Proteica | CinnaGen Co | Pre-clínica |
Protein Subunit Adenoviral Carrier | Subunidad Proteica | CEA CNRS | Pre-clínica |
Protein Subunit Nanoformulated | Subunidad Proteica | Vaxinano CEA INRAE | Pre-clínica |
Soluble recombinant S protein produced in CHO cells | Subunidad Proteica | Center for Advanced Technologies Uzbekistan | Pre-clínica |
Adjuvanted Peptides + Recombinant Spike Protein | Subunidad Proteica | Yıldız Technical University Turkey | Pre-clínica |
NYVAC-KC, attenuated vaccinia virus vector expressing SARS-CoV-2 Spike and other viral proteins | Subunidad Proteica | Arizona State University | Pre-clínica |
Desconocida | VLP | Doherty Institute | Pre-clínica |
ADDomerTM con display de multiepítopo | VLP | Imophoron Ltd and Bristol University’s Max Planck Centre | Pre-clínica |
Protein DC-targeted epitopes | Subunidad Proteica | LinkinVax VRI Inserm | Pre-clínica |
Lentiviral Vector Retro-VLP Particles | Vector viral no replicante | Sorbonne University | Pre-clínica |
Partículas pseudovíricas, basada en RBD de VLP | VLP | Saiba GmbH | Pre-clínica |
Sendai virus vector | Vector viral no replicante | Max Planck Institute for Biochemstry / vir4vac Germany | Pre-clínica |
Spiked-based | Subunidad Proteica | Nanografi Nano Technology Middle East Technical University Ankara University | Pre-clínica |
Lentiviral Vector | Vector viral no replicante | AIOVA | Pre-clínica |
Adenovirus Type 5 Vector | Vector viral no replicante | Globe Biotech Limited / Bangladesh | Pre-clínica |
Sendai virus vector | Vector viral no replicante | ID Pharma | Pre-clínica |
Codon deoptimized live attenuated vaccines | Virus vivo atenuado | Mehmet Ali Aydinlar University / Acıbadem Labmed Health Services A.S | Pre-clínica |
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018 | Inactivada | Institute Butantan (Brazil) / Dynavax / PATH | Pre-clínica |
Cross-reactive T-cell recombinant vaccine based on SARS-CoV-2 nucleoprotein (N) expressed in E.coli | Subunidad Proteica | FSUE SPbSRIVS FMBA of Russia (St. Petersburg Institute of Vaccines) | Pre-clínica |
Partículas pseudovíricas, vehículos lentivirus y baculovirus | VLP | Oncoimmunology group | Pre-clínica |
VLP + adyuvante | VLP | Mahidol University/ The Government Pharmaceutical Organization (GPO) | Pre-clínica |
DNA plasmids containing S-gene | ADN | Biosun Pharmed | Pre-clínica |
Adeno5-based | Vector viral no replicante | Erciyes University | Pre-clínica |
mRNA | ARN | Selcuk University | Pre-clínica |
ARNm | ARN | IDIBAPS-Hospital Clinic Spain | Pre-clínica |
RBD-protein | Subunidad Proteica | Mynvax | Pre-clínica |
Peptide + novel adjuvant | Subunidad Proteica | Bogazici University | Pre-clínica |
Inactivada | Inactivada | Erciyes University | Pre-clínica |
Newcastle disease virus expressing membrane-anchored spike | Vector viral no replicante | Icahn School of Medicine at Mount Sinai | Pre-clínica |
Inactivated whole virus | Inactivada | National Research Centre/Egypt | Pre-clínica |
ARNm | ARN | Greenlight Biosciences | Pre-clínica |
ARNm en sistema de administración intranasal | ARN | eTheRNA | Pre-clínica |
Recombinant S protein | Subunidad Proteica | Max-Planck-Institute of Colloids and Interfaces | Pre-clínica |
Self-amplifying RNA | ARN | Gennova | Pre-clínica |
RBD protein delivered in mannoseconjugated chitosan nanoparticle | Subunidad Proteica | Ohio State University / Kazakh National Agrarian University | Pre-clínica |
DNA plasmid vaccine S,S1,S2,RBD &N | ADN | National Research Centre/Egypt | Pre-clínica |
ARNm de LNP | ARN | Chula Vaccine Research Center/University of Pennsylvania | Pre-clínica |
VSV-S | Vector viral replicante | Aurobindo | Pre-clínica |
Peptides | Subunidad Proteica | Neo7Logic | Pre-clínica |
Enveloped Virus-Like Particle (eVLP) | VLP | VBI Vaccines Inc. | Pre-clínica |
Recombinant spike protein with Essai O/W 1849101 adjuvant | Subunidad Proteica | Kazakh National Agrarian University Kazakhstan / National Scientific Center for Especially Dangerous Infections | Pre-clínica |
ARNm | ARN | China CDC/Tongji University/Stermina | Pre-clínica |
VLP | VLP | Middle East Technical University | Pre-clínica |
Recombinant S protein | Subunidad Proteica | Izmir Biomedicine and Genome Center | Pre-clínica |
Inactivated + Alum | Inactivada | Shifa Pharmed | Pre-clínica |
Protein Subunit S,N,M&S1 protein | Subunidad Proteica | National Research Centre/Egypt | Pre-clínica |
Inactivada | Inactivada | Selcuk University | Pre-clínica |
Virus-like particle-based Dendritic Cell(DC)- targeting vaccine | VLP | University of Manitoba | Pre-clínica |
Inactivated | Inactivada | Zista Kian Azma Co | Pre-clínica |
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018 | Inactivada | Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax / PATH | Pre-clínica |
Plant derived VLP | VLP | Shiraz University | Pre-clínica |
Recombinant S protein produced in BEVS | Subunidad Proteica | Tampere University | Pre-clínica |
Varios candidatos de ARNm | ARN | RNAimmune Inc | Pre-clínica |
VLP | VLP | Bezmialem Vakif University | Pre-clínica |
MVA expressing structural proteins | Vector viral no replicante | Centro Nacional Biotecnología (CNB-CSIC) Spain | Pre-clínica |
RBD protein (baculovirus production) + FARSqualene adjuvant | Subunidad Proteica | Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH) | Pre-clínica |
D614G variant LNP-encapsulated mRNA | ARN | Globe Biotech Ltd | Pre-clínica |
ARNm encapsulado en liposomas | ARN | BIOCAD | Pre-clínica |
ARNm encapsulado en LNP | ARN | University of Tokyo/ Daiichi- Sankyo | Pre-clínica |
Adenovirus-based | Vector viral no replicante | Ankara University | Pre-clínica |
Influenza A H1N1 vector | Vector viral no replicante | National Research Centre/Egypt | Pre-clínica |
S-Protein (Subunit) + Adjuvant, E coli based Expression | Subunidad Proteica | Helix Biogen Consult. Ogbomoso & Trinity Immonoefficient Laboratory/Ogbomoso. Oyo State/Nigeria. | Pre-clínica |
Replicación de ARN derivados de SARS-CoV-2 defectuoso | ARN | Centro Nacional Biotecnología (CNB-CSIC) Spain | Pre-clínica |
DNA vaccine | ADN | Ege University | Pre-clínica |
ARNm encapsulado en LNP que codifica RBD | ARN | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma | Pre-clínica |
Cóctel de ARNm encapsulado en LNP que codifica VLP | ARN | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma | Pre-clínica |
LNP-mRNA | ARN | CanSino Biologics/Precision NanoSystems | Pre-clínica |
ARNm de LNP | ARN | Translate Bio/Sanofi Pasteur socio CAEME | Pre-clínica |
DNA plasmid vaccine RBD&N | ADN | Scancell/University of Nottingham/ Nottingham Trent University | Pre-clínica |
Subunidad proteica | Subunidad Proteica | Research Institute for Biological Safety Problems/Rep of Kazakhstan | Pre-clínica |
Vector de paramixovirus aviar (APMV) | Vector viral replicante | The Lancaster University UK | Pre-clínica |
S subunit intranasal liposomal formulation with GLA/3M052 adjs. | Subunidad Proteica | University of Virginia | Pre-clínica |
Recombinant protein | Subunidad Proteica | Yisheng Biopharma | Pre-clínica |
Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD | Vector de bacteria replicante | Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH) | Pre-clínica |
Vector del virus de la enfermedad de Newcastle (NDV- SARS-CoV-2/Espiga) | Vector viral replicante | Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ | Pre-clínica |
Inactivated | Inactivada | Milad Pharmaceutics Co | Pre-clínica |
Vector de influenza de replicación única sin M2 | Vector viral replicante | UW–Madison/FluGen/Bharat Biotech | Pre-clínica |
Inactivated + alum | Inactivada | KM Biologics | Pre-clínica |
Vector VSV | Vector viral replicante | FBRI SRC VB VECTOR Rospotrebnadzor Koltsovo | Pre-clínica |
VSV-S | Vector viral replicante | University of Western Ontario | Pre-clínica |
Vector de influenza expresando RBD | Vector viral replicante | University of Hong Kong | Pre-clínica |
Influenza atenuada que expresa una porción antigénica de la proteína S | Vector viral replicante | Fundação Oswaldo Cruz and Instituto Buntantan | Pre-clínica |
Inactivada | Inactivada | Kocak Farma Ilac ve Kimya San. A.S. | Pre-clínica |
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018 | Inactivada | Government Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH | Pre-clínica |
Ad 5 vector for intranasal administration | Vector viral no replicante | University of Helsinki & University of Eastern Finland | Pre-clínica |
Vacuna recombinante basada en el virus de la influenza A, para la prevención de COVID- 19 (intranasal) | Vector viral replicante | FBRI SRC VB VECTOR Rospotrebnadzor Koltsovo | Pre-clínica |
Vacuna viva viral vectorizada basada en la cadena atenuada del virus de la influenza (intranasal) | Vector viral replicante | BiOCAD and IEM | Pre-clínica |
Vector de HSPV expresando proteína S | Vector viral replicante | Tonix Pharma/Southern Research | Pre-clínica |
Virus del sarampión (objetivos S, N) | Vector viral replicante | DZIF – German Center for Infection Research | Pre-clínica |
mRNA | ARN | Providence Therapeutics | Pre-clínica |
Vector de sarampión | Vector viral replicante | FBRI SRC VB VECTOR Rospotrebnadzor Koltsovo | Pre-clínica |
DNA plasmid vaccine | ADN | Globe Biotech Limited / Bangladesh | Pre-clínica |
Vector de sarampión | Vector viral replicante | Zydus Cadila | Pre-clínica |
Vector YF17D | Vector viral replicante | KU Leuven | Pre-clínica |
Basada en espiga (barrido de epítopo) | Subunidad Proteica | ImmunoPrecise | Pre-clínica |
Péptido de vesícula de membrana externa (OMV) | Subunidad Proteica | Intravacc/Epivax | Pre-clínica |
Subunidad de vesícula de membrana externa (OMV) | Subunidad Proteica | Intravacc/Epivax | Pre-clínica |
Basada en RBD | Subunidad Proteica | Neovii/Tel Aviv University | Pre-clínica |
Subunidad proteica | Subunidad Proteica | MOGAM Institute for Biomedical Research GC Pharma | Pre-clínica |
Péptidos derivados de Proteína de espiga | Subunidad Proteica | Axon Neuroscience SE | Pre-clínica |
Administración oral, subunidad estable al calor | Subunidad Proteica | Applied Biotechnology Institute Inc | Pre-clínica |
Proteína S recombinante en sistema de vector de expresión de baculovirus de células de insecto (IC-BEVS) | Subunidad Proteica | Vabiotech | Pre-clínica |
Proteína de fusión recombinante S1-Fc | Subunidad Proteica | AnyGo Technology | Pre-clínica |
Basado en espiga | Subunidad Proteica | University of Alberta | Pre-clínica |
Partículas esféricas estructuralmente modificadas del virus del mosaico del tabaco (TMV) | Subunidad Proteica | Lomonosov Moscow State University | Pre-clínica |
Vacuna basada en OMV | Subunidad Proteica | BiOMViS Srl/Univ of Trento | Pre-clínica |
Plasmid DNA, Needle-Free Delivery | ADN | Immunomic Therapeutics Inc./EpiVax Inc. | Pre-clínica |
LNP-encapsulated mRNA encoding S | ARN | Max-Planck-Institute of Colloids and Interfaces | Pre-clínica |
Plasmid DNA, nanostructured RBD | ADN | National institute of Chemistry Slovenia | Pre-clínica |
Vacuna basada en OMV | Subunidad Proteica | Quadram Institute Biosciences | Pre-clínica |
Subunidad basada en vegetales (RBD-Fc + Adyuvante) | Subunidad Proteica | Baiya Phytopharm/ Chula Vaccine Research Center | Pre-clínica |
Vacuna de nanopartículas | Subunidad Proteica | LakePharma Inc. | Pre-clínica |
Sistema de expresión de proteínas S y N basado en vacunal oral E. coli | Subunidad Proteica | MIGAL Galilee Research Institute | Pre-clínica |
mRNA | ARN | Cell Tech Pharmed | Pre-clínica |
Vacuna candidata de péptido largo sintético para proteínas S y M | Subunidad Proteica | OncoGen | Pre-clínica |
Potenciada – péptido de microesferas | Subunidad Proteica | VIDO-InterVac University of Saskatchewan | Pre-clínica |
COVID-19 XWG-03 – proteínas truncadas S (espiga) | Subunidad Proteica | Innovax/Xiamen Univ/GSK socio CAEME | Pre-clínica |
Proteína recombinante, nanopartículas (a base de proteína S y otros epítopos) | Subunidad Proteica | Saint-Petersburg scientific research institute of vaccines and serums | Pre-clínica |
Subunidad proteica, Fuente vegetal | Subunidad Proteica | iBio/CC-Pharming | Pre-clínica |
Proteína S1 o RBD | Subunidad Proteica | Baylor College of Medicine | Pre-clínica |
Vacuna de subunidades | Subunidad Proteica | FBRI SRC VB VECTOR Rospotrebnadzor Koltsovo | Pre-clínica |
Cadena principal gp-96 | Subunidad Proteica | Heat Biologics/Univ. Of Miami | Pre-clínica |
Vacuna peptídica | Subunidad Proteica | FBRI SRC VB VECTOR Rospotrebnadzor Koltsovo | Pre-clínica |
Subunidad de Proteína EPV- CoV-19 | Subunidad Proteica | EpiVax | Pre-clínica |
saRNA formulated in a NLC | ARN | Infectious Disease Research Institute/ Amyris Inc | Pre-clínica |
Proteína S | Subunidad Proteica | EpiVax/Univ of Georgia | Pre-clínica |
Péptido Ii-Key | Subunidad Proteica | Generex/EpiVax | Pre-clínica |
Proteína S | Subunidad Proteica | AJ Vaccines | Pre-clínica |
Péptido | Subunidad Proteica | Flow Pharma Inc | Pre-clínica |
Péptido | Subunidad Proteica | Vaxil Bio | Pre-clínica |
Subunidad S1 con Matriz de microagujas | Subunidad Proteica | University of Pittsburgh | Pre-clínica |
Proteína recombinante de VLP + adyuvante | Subunidad Proteica | Japan | Pre-clínica |
Proteína S + adyuvante | Subunidad Proteica | National Institute of Infectious Disease Japan | Pre-clínica |
Proteína S | Subunidad Proteica | WRAIR/USAMRIID | Pre-clínica |
Antígenos peptídicos formulados en LNP | Subunidad Proteica | IMV Inc | Pre-clínica |
VLP del sistema de expresión de células S2 de insecto Drosophila | Subunidad Proteica | ExpreS2ion | Pre-clínica |
Partícula tipo cápside | Subunidad Proteica | AdaptVac (PREVENT-nCoV consortium) | Pre-clínica |
Dominio de unión al receptor (RBD) en la proteína de fusión con región constante (Fc) de la inmunoglobulina G (IgG) + Adyuvante. | Subunidad Proteica | Chulalongkorn University/GPO Thailand | Pre-clínica |
Subunidad proteica | Subunidad Proteica | University of San Martin and CONICET Argentina | Pre-clínica |
Vacuna inactivada contra el SARS-CoV2 basada en influenza + Potenciador | Vector viral no replicante | National Center for Genetic Engineering and Biotechnology (BIOTEC) /GPO Thailand | Pre-clínica |
viral de la rabia recombinante desactivada que contiene S1 | Vector viral no replicante | Bharat Biotech/Thomas Jefferson University | Fase 1 |
Vacuna basada en el virus de la parainfluenza 5 (PIV5) que expresa la proteína S | Vector viral no replicante | University of Georgia/University of Iowa | Pre-clínica |
Measles Vector | Vector viral no replicante | Cadila Healthcare Limited | Pre-clínica |
Vacuna basada en células dendríticas | Vector viral no replicante | University of Manitoba | Pre-clínica |
Proteínas estructurales que expresan MVA | Vector viral no replicante | Centro Nacional Biotecnología (CNB-CSIC) | Pre-clínica |
basada en adenovirus + péptidos unidos al antígeno leucocitario humano (HLA) | Vector viral no replicante | Valo Therapeutics Ltd | Pre-clínica |
Ad5 S oral | Vector viral no replicante | Stabilitech Biopharma Ltd | Pre-clínica |
Ad5 S (plataforma GREVAX™) | Vector viral no replicante | Greffex | Pre-clínica |
Recombinant spike with adjuvant | Subunidad Proteica | Iran | Pre-clínica |
NasoVAX basada en adenovirus que expresa la proteína S de SARS2-CoV | Vector viral no replicante | Altimmune | Pre-clínica |
MVA-S | Vector viral no replicante | IDIBAPS-Hospital Clinic Spain | Pre-clínica |
Codificada con MVA-S | Vector viral no replicante | DZIF – German Center for Infection Research | Pre-clínica |
Partículas pseudovíricas (VLP) codificadas con MVA | Vector viral no replicante | GeoVax/BravoVax | Pre-clínica |
Vector de virus adeno-asociado (AAVCOVID) | Vector viral no replicante | Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis | Pre-clínica |
Newcastle disease virus expressing S | Vector viral no replicante | Icahn School of Medicine at Mount Sinai | Pre-clínica |
Vacuna viva atenuada desoptimizada por codones | Virus vivo atenuado | Indian Immunologicals Ltd/Griffith University | Pre-clínica |
Vacuna viva atenuada desoptimizada por codones | Virus vivo atenuado | Codagenix/Serum Institute of India | Pre-clínica |
mRNA | ARN | ReNAP Co | Pre-clínica |
Inactivada + CpG 1018 | Inactivada | Valneva/Dynavax | Pre-clínica |
Inactivada + CpG 1018 | Inactivada | Sinovac/Dynavax | Pre-clínica |
TBD | Inactivada | Osaka University/ BIKEN/ NIBIOHN | Pre-clínica |
Vacuna de ADN | ADN | Entos Pharmaceuticals | Pre-clínica |
Vacuna de ADN | ADN | University of Waterloo | Pre-clínica |
ADN plasmídico, de inyección sin aguja | ADN | Inc./PharmaJet | Pre-clínica |
Vacuna de ADN | ADN | BioNet Asia | Pre-clínica |
VLP | VLP | Max Planck Institute for Dynamics of Complex Technical Systems | Pre-clínica |
AND | ADN | Takis/Applied DNA Sciences/Evvivax | Pre-clínica |
CD8 T cell peptide targeting (S, M, N) and (NSPs) SARS-CoV-2 proteins | T-cell based | OSE immunotherapeutics | Pre-clínica |
ADN con electroporación | ADN | Chula Vaccine Research Center | Pre-clínica |
VLPs produced in BEVS | VLP | Tampere University | Pre-clínica |
ADN con electroporación | ADN | Karolinska Institute / Cobra Biologics (OPENCORONA Project) | Pre-clínica |